Valneva's Zika vaccine candidate – VLA1601
Zika is a mosquito-borne disease associated with birth defects
The most common symptoms of Zika virus infection are mild fever, skin rash and conjunctivitis (pink eye) lasting between two to seven days. Global health officials are alarmed because of its link to brain defects in infants as well as the rare Guillain-Barré syndrome that can lead to paralysis.
In November 2018, Valneva and Emergent BioSolutions Inc. reported positive interim results for the Phase 1 study evaluating VLA1601, their vaccine candidate against the Zika virus (see press release).
The Phase 1 study was designed to assess safety and immunogenicity. It is being co-financed by Emergent and Valneva as part of an exclusive, worldwide license agreement signed in July 2017. The agreement includes pre-defined post-Phase 1 opt-in rights for Emergent.